Basolo F, Pollina L, Pacini F, Fontanini G, Ménard S, Castronovo V, Bevilacqua G
Institute of Pathology, University of Pisa, Via Roma 57, 56126 Pisa, Italy.
Clin Cancer Res. 1996 Oct;2(10):1777-80.
Increased expression of the Mr 67,000 laminin receptor (LR) is a consistent event which appears as cancer cells acquire an invasive and metastatic phenotype. The Mr 67,000 LR is one of the many laminin-binding proteins able to interact with the major glycoprotein of basement membranes, laminin. The recent development of a specific monoclonal antibody directed against the Mr 67,000 LR MLuC5 has allowed us to study large retrospective groups of human cancers with the aim of correlating the Mr 67,000 LR expression to the clinical, pathological, and survival data of the patients. A significant correlation has already been established between the increased expression of Mr 67,000 LR and survival of patients with breast, colon, ovary, lung, and endometrial cancers. In this study, we investigated the possibility that the detection of Mr 67,000 LR in thyroid human cancers could also be of prognostic value. We analyzed the expression of Mr 67,000 LR with immunohistochemistry using MLuC5 antibodies in paraffin sections of 40 benign and 170 malignant thyroid human tumors. We found that Mr 67,000 LR was not usually detectable in normal thyroid tissues adjacent to the lesion. Only 3 of the 40 thyroid adenomas examined (7.5%) presented cells positive for Mr 67,000 LR. For the malignant thyroid tumors examined, we found that 22.3% of papillary thyroid carcinomas, 38% of follicular thyroid carcinomas, 40% of poorly differentiated carcinomas, 25% of medullary carcinomas, and 58.3% of anaplastic carcinomas expressed a high level of Mr 67,000 LR. Although no correlation between the Mr 67,000 LR expression and survival was found in patients with follicular thyroid carcinomas, papillary thyroid carcinomas, anaplastic carcinomas, and medullary carcinomas, there was a significant correlation in primary thyroid cancers. Our data represent the first extensive study of the Mr 67,000 LR expression in human thyroid cancers and strongly suggest that its detection could be of prognostic value in the investigation of primary thyroid cancers.
分子量为67,000的层粘连蛋白受体（LR）表达增加是癌细胞获得侵袭性和转移表型时的一个常见现象。分子量为67,000的LR是众多能够与基底膜主要糖蛋白层粘连蛋白相互作用的层粘连蛋白结合蛋白之一。最近针对分子量为67,000的LR开发的特异性单克隆抗体MLuC5，使我们能够研究大量回顾性人类癌症群体，目的是将分子量为67,000的LR表达与患者的临床、病理和生存数据相关联。分子量为67,000的LR表达增加与乳腺癌、结肠癌、卵巢癌、肺癌和子宫内膜癌患者的生存之间已经建立了显著相关性。在本研究中，我们调查了在人类甲状腺癌中检测分子量为67,000的LR是否也具有预后价值。我们使用MLuC5抗体通过免疫组织化学分析了40例良性和170例恶性人类甲状腺肿瘤石蜡切片中分子量为67,000的LR表达。我们发现，在病变附近的正常甲状腺组织中通常检测不到分子量为67,000的LR。在所检查的40例甲状腺腺瘤中，只有3例（7.5%）的细胞对分子量为67,000的LR呈阳性。对于所检查的恶性甲状腺肿瘤，我们发现22.3%的乳头状甲状腺癌、38%的滤泡状甲状腺癌、40%的低分化癌、25%的髓样癌和58.3%的间变性癌表达高水平的分子量为67,000的LR。虽然在滤泡状甲状腺癌、乳头状甲状腺癌、间变性癌和髓样癌患者中未发现分子量为67,000的LR表达与生存之间的相关性，但在原发性甲状腺癌中存在显著相关性。我们的数据代表了对人类甲状腺癌中分子量为67,000的LR表达的首次广泛研究，并强烈表明其检测在原发性甲状腺癌的研究中可能具有预后价值。
